Skip to main content
Clinical Trials/CTRI/2021/09/036701
CTRI/2021/09/036701
Completed
未知

Immediate procedural safety and long-term efficacy of Ultra-long 48 mm Xience-Xpedition stents: A real world experience from India

Department of Cardiology0 sites92 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: Z988- Other specified postprocedural states
Sponsor
Department of Cardiology
Enrollment
92
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 4, 2021
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Department of Cardiology

Eligibility Criteria

Inclusion Criteria

  • All patients who underwent percutaneous coronary intervention using
  • Xience Xpedition 48 mm long stent (Abbott vascular  Santa Clara, CA ) who
  • will be willing to give informed consent

Exclusion Criteria

  • Patients who will not give consent
  • Patients who could not be contacted

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Procedural Safety and Long term Clinical Outcomes in Patients with coronary artery disease
CTRI/2024/02/062793Sri Ramachandra Institute of Higher Education and Research
Recruiting
Phase 1
Short-term and long-term efficacy and safety evaluation of acupoint catgut embedding in the simple obesity: a randomized controlled double-blind trial
ITMCTR2200005494The Fifth Affiliated Hospital of Southern Medical University
Completed
Not Applicable
Efficacy trial and long-term safety confirmation test- Efficacy and long-term safety of the test food TK61406 ingested as a single dose, in a double-blind, parallel-group comparison to placebo.A range of individuals from healthy to borderline conditions- Persons with tendency for constipation or diarrhea- Persons classified as normal to 1 degree of obesity- Persons classified with normal to 1 degree of average blood pressure
JPRN-jRCT1091220210Tokai Pickling Co.,Ltd. Yasufumi Ohba, Masataka Fujita, Mitsuru Satsukawa, Tetsuhiro Kawamoto, Mika Komura, Shoko Nishio, Tetsuya Iyoda,Hiroshi Ono30
Completed
Phase 4
Evaluation of Long-term efficacy, safety and predictors of Adalimumab in Crohn's disease: Japanese multicenter cohort study (ADJUST study)
JPRN-UMIN000014708IBD Center, Sapporo Kosei General Hospital500
Active, not recruiting
Phase 1
Follow-Up clinical trial in patients who have previously received test product RG-101 for assessment of long term safety and efficacyHepatitis C PatientsMedDRA version: 19.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: LLTClassification code 10019761Term: Hepatitis cytomegalovirusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: LLTClassification code 10057394Term: Hepatitis C positiveSystem Organ Class: 100000004848MedDRA version: 19.0Level: LLTClassification code 10019760Term: Hepatitis CMVSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2016-002069-77-HURegulus Therapeutics Inc.200